Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 67 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Pentheroudakis, George  [Clear All Filters]
Journal Article
Strati, T-M., Kotoula V., Kostopoulos I., Manousou K., Papadimitriou C., Lazaridis G., et al. (2017).  Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer.. Anticancer Res. 37(5), 2323-2334.
Pentheroudakis, G., Batistatou A., Kalogeras K. T., Kronenwett R., Wirtz R. M., Bournakis E., et al. (2011).  Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.. Breast Cancer Res Treat. 127(1), 179-93.
Zagouri, F., Kotoula V., Kouvatseas G., Sotiropoulou M., Koletsa T., Gavressea T., et al. (2017).  Protein expression patterns of cell cycle regulators in operable breast cancer.. PLoS One. 12(8), e0180489.
Pectasides, D., Karavasilis V., Papaxoinis G., Gourgioti G., Makatsoris T., Raptou G., et al. (2015).  Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or. BMC Cancer. 15, 384.
Papadimitriou, C. A., Papakostas P., Karina M., Malettou L., Dimopoulos M. A., Pentheroudakis G., et al. (2011).  A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.. BMC Med. 9, 10.
Kotoula, V., Tsakiri K., Koliou G-A., Lazaridis G., Papadopoulou K., Giannoulatou E., et al. (2019).  Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.. Clin Breast Cancer. 19(2), 113-125.e4.
Razis, E., Kalogeras K. T., Kotsantis I., Koliou G-A., Manousou K., Wirtz R., et al. (2020).  The Role of CXCL13 and CXCL9 in Early Breast Cancer.. Clin Breast Cancer. 20(1), e36-e53.
Papaxoinis, G., Kotoula V., Alexopoulou Z., Kalogeras K. T., Zagouri F., Timotheadou E., et al. (2015).  Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.. PLoS One. 10(10), e0140293.
Pentheroudakis, G., Kotoula V., Fountzilas E., Kouvatseas G., Basdanis G., Xanthakis I., et al. (2014).  A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).. BMC Cancer. 14, 111.
Kostopoulos, I., Karavasilis V., Karina M., Bobos M., Xiros N., Pentheroudakis G., et al. (2009).  Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.. BMC Cancer. 9, 339.
Fountzilas, G., Christodoulou C., Bobos M., Kotoula V., Eleftheraki A. G., Xanthakis I., et al. (2012).  Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.. J Transl Med. 10, 212.
Fountzilas, G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., et al. (2016).  TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.. Oncotarget. 7(22), 32731-53.
Pentheroudakis, G., Angouridakis N., Wirtz R., Nikolaou A., Kalogeras K. T., Pavlidis N., et al. (2009).  Transcriptional activity of human epidermal growth factor receptor family and angiogenesis effectors in locoregionally recurrent head and neck squamous cell carcinoma and correlation with patient outcome.. J Oncol. 2009, 854127.
Kotoula, V., Lakis S., Vlachos I. S., Giannoulatou E., Zagouri F., Alexopoulou Z., et al. (2016).  Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes.. PLoS One. 11(9), e0163138.
Nikolaidi, A., Kotoula V., Koliou G-A., Giannoulatou E., Papadopoulou K., Zagouri F., et al. (2020).  Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer.. Cancer Genomics Proteomics. 17(2), 181-193.
Kotoula, V., Chatzopoulos K., Lakis S., Alexopoulou Z., Timotheadou E., Zagouri F., et al. (2016).  Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.. Oncotarget. 7(4), 5074-87.
Pectasides, D., Papaxoinis G., Kalogeras K. T., Eleftheraki A. G., Xanthakis I., Makatsoris T., et al. (2012).  XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.. BMC Cancer. 12, 271.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές